DE69623652T2 - Formulierung zur peptidfreisetzung - Google Patents

Formulierung zur peptidfreisetzung

Info

Publication number
DE69623652T2
DE69623652T2 DE69623652T DE69623652T DE69623652T2 DE 69623652 T2 DE69623652 T2 DE 69623652T2 DE 69623652 T DE69623652 T DE 69623652T DE 69623652 T DE69623652 T DE 69623652T DE 69623652 T2 DE69623652 T2 DE 69623652T2
Authority
DE
Germany
Prior art keywords
formulation
deslorelin
stearin
lecithin
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69623652T
Other languages
German (de)
English (en)
Other versions
DE69623652D1 (de
Inventor
Elliot Trigg
Desmond Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virbac Australia Pty Ltd
Original Assignee
Peptech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech Ltd filed Critical Peptech Ltd
Application granted granted Critical
Publication of DE69623652D1 publication Critical patent/DE69623652D1/de
Publication of DE69623652T2 publication Critical patent/DE69623652T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69623652T 1995-06-20 1996-06-20 Formulierung zur peptidfreisetzung Expired - Lifetime DE69623652T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN3667A AUPN366795A0 (en) 1995-06-20 1995-06-20 Formulation for preventing reproductive function
PCT/AU1996/000370 WO1997000693A1 (en) 1995-06-20 1996-06-20 Novel formulation for peptide release

Publications (2)

Publication Number Publication Date
DE69623652D1 DE69623652D1 (de) 2002-10-17
DE69623652T2 true DE69623652T2 (de) 2003-05-28

Family

ID=3788008

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69623652T Expired - Lifetime DE69623652T2 (de) 1995-06-20 1996-06-20 Formulierung zur peptidfreisetzung
DE122008000004C Active DE122008000004I2 (de) 1995-06-20 1996-06-20 Formulierung zur peptidfreisetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122008000004C Active DE122008000004I2 (de) 1995-06-20 1996-06-20 Formulierung zur peptidfreisetzung

Country Status (16)

Country Link
US (2) US5925619A (enExample)
EP (1) EP0871467B1 (enExample)
JP (1) JP4016133B2 (enExample)
CN (1) CN1145496C (enExample)
AT (1) ATE223726T1 (enExample)
AU (2) AUPN366795A0 (enExample)
CA (1) CA2225796C (enExample)
DE (2) DE69623652T2 (enExample)
DK (1) DK0871467T3 (enExample)
ES (1) ES2182983T3 (enExample)
FR (1) FR08C0001I2 (enExample)
NL (1) NL300330I2 (enExample)
NZ (1) NZ309697A (enExample)
PT (1) PT871467E (enExample)
SI (1) SI0871467T1 (enExample)
WO (1) WO1997000693A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
CA2264562C (en) 1996-08-30 2012-01-03 Peptech Limited Sustained peptide-release formulation
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
US8052982B2 (en) * 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
US6211221B1 (en) * 1999-04-05 2001-04-03 Johnny W. Peterson Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
CA2552241C (en) * 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
US20080254086A1 (en) * 2004-12-23 2008-10-16 Brown James E Controlled Release Compositions
KR20100059863A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도
DE102008015104A1 (de) 2008-03-19 2009-09-24 Basf Coatings Ag Beschichtungszusammensetzung, Verfahren zu ihrer Herstellung, ihre Verwendung und mit ihr beschichtete Substrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563846B2 (enExample) * 1972-10-12 1981-01-27
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function

Also Published As

Publication number Publication date
AU701837B2 (en) 1999-02-04
EP0871467A4 (en) 2000-07-05
NL300330I1 (nl) 2008-03-03
CN1188414A (zh) 1998-07-22
DE122008000004I1 (de) 2008-04-17
NZ309697A (en) 1999-11-29
DK0871467T3 (da) 2002-12-23
JP4016133B2 (ja) 2007-12-05
CN1145496C (zh) 2004-04-14
CA2225796A1 (en) 1997-01-09
CA2225796C (en) 2011-09-20
AUPN366795A0 (en) 1995-07-13
HK1014874A1 (en) 1999-10-08
DE122008000004I2 (de) 2009-08-06
EP0871467A1 (en) 1998-10-21
FR08C0001I1 (enExample) 2008-03-21
PT871467E (pt) 2002-12-31
JP2001521482A (ja) 2001-11-06
US5925619A (en) 1999-07-20
NL300330I2 (nl) 2008-04-01
DE69623652D1 (de) 2002-10-17
FR08C0001I2 (enExample) 2009-11-20
EP0871467B1 (en) 2002-09-11
ES2182983T3 (es) 2003-03-16
WO1997000693A1 (en) 1997-01-09
US6211152B1 (en) 2001-04-03
ATE223726T1 (de) 2002-09-15
AU5992796A (en) 1997-01-22
SI0871467T1 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
DE69737635T2 (de) Formulierung zur verzögerten Freisetzung von Peptidagonisten und -analoga des GnRH
DE69926504T2 (de) Zubereitungen zur kontrollierten freisetzung mit mehrschichtstruktur
DE69432990T2 (de) PROGESTAGEN-FREIE FORMULIERUNGEN VON GnRH UND ESTROGEN ZUR BEHANDLUNG VON BENIGNEN GYNÄKOLOGISCHEN STÖRUNGEN
DE60027272T2 (de) Stabile, nichtwässrige, einphasige, biokompatible, viskose Träger und Formulierungen, die diese Träger verwenden
DE69738048T2 (de) Vorrichtung zur lokalen verabreichung von fest-oder halbfesten pharmazeutischen zusammensetzungen
DE69230040T2 (de) Biokompatibles implantat für die zeitliche abstimmung der ovulation von stuten
DE69728371T2 (de) Verfahren zur herstellung von implantaten, die leuprolid enthalten
DE69722620T2 (de) Nicht-waessrige protische peptidzubereitungen
DE69908326T2 (de) Pharmazeutische zusammensetzungen für die verzögerte freisetzung von peptiden und verfahren zu deren herstellung
DE3875160T2 (de) Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga.
DE69009743T2 (de) Dosierungsform für dauerverabreichung.
DE68928528T2 (de) Verwendung von GnRH, LHRH oder ihre Derivate enthaltende Zubereitungen mit verzögerter Wirkstofffreisetzung
EP1073426B1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
DE69902852T2 (de) Implantat enthaltend einen Silikonkern zur Langzeitfreigabe von Androgenen
DE60132072T2 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
US5925619A (en) Formulation for peptide release
DE69231263T2 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen
EP3131532A1 (de) Veterinärpharmazeutische zusammensetzung und deren verwendung
DE69001540T2 (de) Arzneimittel zur rektalen verabreichung von calcitonin.
DE69711773T2 (de) Ovulation auslösende arzneistoffe enthaltend luteinisierendes hormon
HK1014874B (en) Novel formulation for peptide release
AU1843899A (en) Novel formulation for peptide release
AU713413B2 (en) Sustained peptide-release formulation
HK1022275B (en) Sustained peptide-release formulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: SUPRELORIN-DESLORELIN ACETATE; REGISTRATION NO/DATE: EU/2/07/072/001, 20070710

Spc suppl protection certif: 12 2008 000 004

Filing date: 20080110

R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

8327 Change in the person/name/address of the patent owner

Owner name: PEPTECH ANIMAL HEALTH PTY LTD., MACQUARIE PARK, AU

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: SUPRELORIN-DESLORELIN ACETATE; REGISTRATION NO/DATE: EU/2/07/072/001, 20070710

Spc suppl protection certif: 12 2008 000 004

Filing date: 20080110

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

V457 Spc granted

Free format text: PRODUCT NAME: SUPRELORIN-DESLORELIN ACETATE; REGISTRATION NO/DATE: EU/2/07/072/001, 20070710

Spc suppl protection certif: 12 2008 000 004

Filing date: 20080110

8328 Change in the person/name/address of the agent

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 805

R078

Free format text: PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

R078

Free format text: PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

R082 Change of representative

Ref document number: 871467

Country of ref document: EP

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE

R081 Change of applicant/patentee

Ref document number: 871467

Country of ref document: EP

Owner name: VIRBAC (AUSTRALIA) PTY. LTD., AU

Free format text: FORMER OWNER: PEPTECH ANIMAL HEALTH PTY LTD., MACQUARIE PARK, AU

Effective date: 20121029

R082 Change of representative

Ref document number: 871467

Country of ref document: EP

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE

Effective date: 20121029

SP81

Owner name: VIRBAC (AUSTRALIA) PTY. LTD., MILPERRA, NSW, AU

Free format text: PREVIOUS APPLICANT: PEPTECH ANIMAL HEALTH PTY LTD., MACQUARIE PARK, NEUSUEDWALES, AU; PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

Owner name: VIRBAC (AUSTRALIA) PTY. LTD., MILPERRA, AU

Free format text: PREVIOUS APPLICANT: PEPTECH ANIMAL HEALTH PTY LTD., MACQUARIE PARK, AU; PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

SP82

Free format text: PREVIOUS REPRESENTATIVE: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 80538 MUENCHEN, DE; PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 80538 MUENCHEN, DE

Free format text: PREVIOUS REPRESENTATIVE: ; PRODUCT NAME: DESLORELINACETAT; AUTHORISATION NO/DATE: EU/2/07/072 20070710

Spc suppl protection certif: 122008000004